Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
Acute myeloid leukemia (AML) with mutated <i>RUNX1</i> (<i>RUNX1</i><sup>mut</sup>) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type <i>RUNX1</i> (<i>RUNX1</i>...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5239 |
| _version_ | 1797468855362125824 |
|---|---|
| author | Tarinee Rungjirajittranon Theerapat Siriwannangkul Smith Kungwankiattichai Nattawut Leelakanok Wannaphorn Rotchanapanya Pongthep Vittayawacharin Benjamaporn Mekrakseree Kamolchanok Kulchutisin Weerapat Owattanapanich |
| author_facet | Tarinee Rungjirajittranon Theerapat Siriwannangkul Smith Kungwankiattichai Nattawut Leelakanok Wannaphorn Rotchanapanya Pongthep Vittayawacharin Benjamaporn Mekrakseree Kamolchanok Kulchutisin Weerapat Owattanapanich |
| author_sort | Tarinee Rungjirajittranon |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) with mutated <i>RUNX1</i> (<i>RUNX1</i><sup>mut</sup>) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type <i>RUNX1</i> (<i>RUNX1</i><sup>wt</sup>). To assess the clinical outcomes of AML with and without <i>RUNX1</i><sup>mut</sup>, we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with <i>RUNX1</i><sup>mut</sup>; 108 with <i>RUNX1</i><sup>w</sup><sup>t</sup>). There were no significant differences in the median OS and RFS of the <i>RUNX1</i><sup>mut</sup> and <i>RUNX1</i><sup>wt</sup> groups (9.1 vs. 12.2 months; <i>p</i> = 0.268 and 7.8 vs. 14.6 months; <i>p</i> = 0.481, respectively). A subgroup analysis of <i>de novo</i> AML patients with intermediate-risk cytogenetics showed similar outcomes. Our meta-analysis pooled data from 23 studies and our study. The complete remission rate was significantly lower in the <i>RUNX1</i><sup>mut</sup> group (pooled odds ratio: 0.42). The OS, RFS, and event-free survival rates also favored the <i>RUNX1</i><sup>wt</sup> group (pooled risk ratios: 1.36, 1.37, and 1.37, respectively). A subgroup analysis of <i>de novo</i> AML patients with intermediate-risk cytogenetics demonstrated nearly identical OS and RFS outcomes. This study confirms that patients with AML and <i>RUNX1</i><sup>mut</sup> had poor prognoses. Nonetheless, in <i>de novo</i> AML with intermediate-risk cytogenetics, the survival outcomes of both groups were comparable. |
| first_indexed | 2024-03-09T19:13:16Z |
| format | Article |
| id | doaj.art-63ad508666f046b5b3d11146e774206a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:13:16Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-63ad508666f046b5b3d11146e774206a2023-11-24T04:01:16ZengMDPI AGCancers2072-66942022-10-011421523910.3390/cancers14215239Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-AnalysisTarinee Rungjirajittranon0Theerapat Siriwannangkul1Smith Kungwankiattichai2Nattawut Leelakanok3Wannaphorn Rotchanapanya4Pongthep Vittayawacharin5Benjamaporn Mekrakseree6Kamolchanok Kulchutisin7Weerapat Owattanapanich8Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDepartment of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi 20131, ThailandDepartment of Medicine, Chiangrai Prachanukroh Hospital, Chiangrai 57000, ThailandDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDivision of Hematology, Department of Medicine, Rajavithi Hospital, Bangkok 10400, ThailandFaculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandAcute myeloid leukemia (AML) with mutated <i>RUNX1</i> (<i>RUNX1</i><sup>mut</sup>) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type <i>RUNX1</i> (<i>RUNX1</i><sup>wt</sup>). To assess the clinical outcomes of AML with and without <i>RUNX1</i><sup>mut</sup>, we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with <i>RUNX1</i><sup>mut</sup>; 108 with <i>RUNX1</i><sup>w</sup><sup>t</sup>). There were no significant differences in the median OS and RFS of the <i>RUNX1</i><sup>mut</sup> and <i>RUNX1</i><sup>wt</sup> groups (9.1 vs. 12.2 months; <i>p</i> = 0.268 and 7.8 vs. 14.6 months; <i>p</i> = 0.481, respectively). A subgroup analysis of <i>de novo</i> AML patients with intermediate-risk cytogenetics showed similar outcomes. Our meta-analysis pooled data from 23 studies and our study. The complete remission rate was significantly lower in the <i>RUNX1</i><sup>mut</sup> group (pooled odds ratio: 0.42). The OS, RFS, and event-free survival rates also favored the <i>RUNX1</i><sup>wt</sup> group (pooled risk ratios: 1.36, 1.37, and 1.37, respectively). A subgroup analysis of <i>de novo</i> AML patients with intermediate-risk cytogenetics demonstrated nearly identical OS and RFS outcomes. This study confirms that patients with AML and <i>RUNX1</i><sup>mut</sup> had poor prognoses. Nonetheless, in <i>de novo</i> AML with intermediate-risk cytogenetics, the survival outcomes of both groups were comparable.https://www.mdpi.com/2072-6694/14/21/5239acute myeloid leukemiageneticmolecularmutationnext-generation sequencing<i>RUNX1</i> |
| spellingShingle | Tarinee Rungjirajittranon Theerapat Siriwannangkul Smith Kungwankiattichai Nattawut Leelakanok Wannaphorn Rotchanapanya Pongthep Vittayawacharin Benjamaporn Mekrakseree Kamolchanok Kulchutisin Weerapat Owattanapanich Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis Cancers acute myeloid leukemia genetic molecular mutation next-generation sequencing <i>RUNX1</i> |
| title | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
| title_full | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
| title_fullStr | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
| title_full_unstemmed | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
| title_short | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
| title_sort | clinical outcomes of acute myeloid leukemia patients harboring the runx1 mutation is it still an unfavorable prognosis a cohort study and meta analysis |
| topic | acute myeloid leukemia genetic molecular mutation next-generation sequencing <i>RUNX1</i> |
| url | https://www.mdpi.com/2072-6694/14/21/5239 |
| work_keys_str_mv | AT tarineerungjirajittranon clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT theerapatsiriwannangkul clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT smithkungwankiattichai clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT nattawutleelakanok clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT wannaphornrotchanapanya clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT pongthepvittayawacharin clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT benjamapornmekrakseree clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT kamolchanokkulchutisin clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT weerapatowattanapanich clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis |